4 Item 1A. Risk Factors 33 Item 1B. Unresolved Staff Comments 71 Item 1C. Cybersecurity 71 Item 2. Properties 72 Item 3. Legal Proceedings 73 Item 4. Mine Safety Disclosures 73 PART II 74 Item 5. Market for Registrants Common Equity, Related Stockholder Matters, and Issuer Purchases of Equity Securities 74 Item 6. Reserved. 74 Item 7. Managements Discussion and Analysis of Financial Condition and Results of Operations 75 Item 7A. Quantitative and Qualitative Disclosures About Market Risk . 88 It...
Q2 FY2026 — expected 2026-08-10
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-03-05 | 2025-12-31 | 0001193125-26-092591 | EDGAR | 81K words |
| 2025-02-27 | 2024-12-31 | 0000950170-25-029129 | EDGAR | — |
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2025-11-06 | 2025-09-30 | 0001193125-25-268116 | EDGAR | 23K words |
| 2025-08-07 | 2025-06-30 | 0000950170-25-104593 | EDGAR | — |
| 2025-05-08 | 2025-03-31 | 0000950170-25-066439 | EDGAR | — |
| Filed | Accession | Source | Full Text |
|---|---|---|---|
| 2026-03-05 | 0001193125-26-092578 | EDGAR | 3K words |
| 2025-12-22 | 0001193125-25-327575 | EDGAR | — |
| 2025-12-15 | 0001193125-25-319156 | EDGAR | — |
| 2025-11-06 | 0001193125-25-268102 | EDGAR | — |
| 2025-10-23 | 0001193125-25-247692 | EDGAR | — |
| 2025-08-14 | 0001193125-25-180313 | EDGAR | — |
| 2025-08-07 | 0001193125-25-174958 | EDGAR | — |
| 2025-06-27 | 0001193125-25-149704 | EDGAR | — |
| 2025-05-08 | 0001193125-25-115533 | EDGAR | — |
| 2025-05-06 | 0001193125-25-113364 | EDGAR | — |
93 total filings indexed. 78 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR
| CIK | 0001479615 |
| Ticker | SLN |
| Exchange | Nasdaq |
| SIC | 2834: Pharmaceutical Preparations |
| Incorporated | X0 |
| Website | https://www.silence-therapeutics.com |
| Listed | 2020-09-08 |
This is the free public profile. For structured JSON with full provenance chain, use the API:
JSON Profile Stock Quote AI Readiness Report